CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological...

CytoMed Therapeutics已在愛文思控股下的首位病人身上投藥，進行了第一期劑量遞增的ANGELICA試驗，該試驗是關於用於治療愛文思控股的Allogeneic NKG2DL靶向嵌合抗原受體移植gamma delta t細胞的高級實體瘤或血液...

Benzinga · 11/20 20:12

CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological Malignancies

CytoMed Therapeutics已經在其首個以人爲對象的I期劑量遞增ANGELICA試驗中對首位患者進行了給藥，該試驗針對的是具有愛文思控股特徵的外源性NKG2DL靶向嵌合抗原受體移植的γδ T細胞，適用於晚期實體腫瘤或血液惡性腫瘤的患者。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。